Xeris Biopharma Holdings, Inc.
Xeris Biopharma Holdings, Inc. (XERS) Financial Performance & Income Statement Overview
Review Xeris Biopharma Holdings, Inc. (XERS) income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Xeris Biopharma Holdings, Inc. (XERS) Income Statement & Financial Overview
Analyze Xeris Biopharma Holdings, Inc.’s XERS earnings with segmented quarterly and yearly financial statement figures.
| Metric | Q1 2025 | Q4 2024 | Q3 2024 |
|---|---|---|---|
| Revenue | $54.27M | $60.10M | $54.27M |
| Cost of Revenue | $13.59M | $9.48M | $13.59M |
| Gross Profit | $40.67M | $50.62M | $40.67M |
| Gross Profit Ratio | $0.75 | $0.84 | $0.75 |
| R&D Expenses | $5.89M | $6.09M | $5.89M |
| SG&A Expenses | $44.97M | $40.14M | $44.97M |
| Operating Expenses | $53.57M | $48.94M | $53.57M |
| Total Costs & Expenses | $67.16M | $58.42M | $67.16M |
| Interest Income | $1.20M | $910000.00 | $1.20M |
| Interest Expense | $7.79M | $7.70M | $7.79M |
| Depreciation & Amortization | $3.12M | $3.13M | $3.12M |
| EBITDA | -$8.15M | $5.72M | -$8.15M |
| EBITDA Ratio | -$0.15 | $0.10 | -$0.15 |
| Operating Income | -$12.89M | $1.68M | -$12.89M |
| Operating Income Ratio | -$0.24 | $0.03 | -$0.24 |
| Other Income/Expenses (Net) | -$6.17M | -$6.79M | -$6.17M |
| Income Before Tax | -$19.06M | -$5.11M | -$19.06M |
| Income Before Tax Ratio | -$0.35 | -$0.09 | -$0.35 |
| Income Tax Expense | -$3.32M | $0.00 | -$3.32M |
| Net Income | -$15.74M | -$5.11M | -$15.74M |
| Net Income Ratio | -$0.29 | -$0.09 | -$0.29 |
| EPS | -$0.11 | -$0.03 | -$0.11 |
| Diluted EPS | -$0.11 | -$0.03 | -$0.11 |
| Weighted Avg Shares Outstanding | $148.99M | $149.09M | $148.99M |
| Weighted Avg Shares Outstanding (Diluted) | $148.99M | $149.09M | $148.99M |
Over the last four quarters, Xeris Biopharma Holdings, Inc.'s revenue moved from $54.27M in Q3 2024 to $54.27M in Q1 2025. Operating income in Q1 2025 was -$12.89M, with a strong operating margin of -24%. Despite fluctuations in R&D and SG&A expenses, EBITDA for Xeris Biopharma Holdings, Inc. remained robust at -$8.15M, reflecting operational efficiency. Net income dropped to -$15.74M, with an EPS of -$0.11. Disciplined expense management helped sustain profitability, highlighting solid overall financial performance.
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan